Dorui Pharmaceutical (301075.SZ) announced that the company recently signed an “Investment Cooperation Agreement”, and the company received it for 200,000 yuan...
Zhitong Finance App News, Dorui Pharmaceutical (301075.SZ) announced that the company recently signed an “Investment Cooperation Agreement”. The company transferred 51% of the shares (unpaid) of Hongxi Medical Technology (Tianjin) Co., Ltd. (“Hongxi Medical”, the “target company”) held by Li Zhanbing, Tian Bin, Zhang Hengrui, and Xiong Rongliang for a registered capital of 5.1 million yuan. The company will invest 5.1 million yuan in Hongxi Medical to fulfill the obligation to pay the capital. After the equity transfer was completed, the company held 51% of Hongxi Medical's shares, and Hongxi Medical is the company's holding subsidiary.
According to reports, Hongxi Medical's core team has many years of experience in the blood purification industry and is committed to becoming a one-stop solution provider for the systematic construction of next-generation smart peritoneal dialysis centers. This foreign investment will help the company enter the field of chronic kidney disease management and create new profit growth points for the company.